Molecule
Ketorolac is a cyclooxygenase inhibitor indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis, among other approved uses. It is available as injection, tablets and eye drops for intramuscular, intravenous and oral use. MedsAcross supplies Ketorolac for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ACULAR is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. ACULAR is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. The treatment of inflammation following cataract surgery.
Source: US FDA prescribing information
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Source: US FDA prescribing information
For temporary relief of ocular itching due to seasonal allergic conjunctivitis, apply one drop of ACULAR to the affected eye(s) four times a day. For the treatment of postoperative inflammation in patients who have undergone cataract extraction, apply one drop of ACULAR to the affected eye four times daily beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
Source: US FDA prescribing information
ACULAR solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation. Hypersensitivity to any component of this product.
Source: US FDA prescribing information
Delayed healing. Cross-sensitivity or hypersensitivity. Increased bleeding time due to interference with thrombocyte aggregation. Corneal effects including keratitis
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Delayed Healing Cross-Sensitivity or Hypersensitivity Increased Bleeding Time Corneal Effects The most frequent adverse reactions reported by up to 40% of patients participating in clinical trials have been transient stinging and burning on instillation.
Source: US FDA prescribing information
Store at 15°C to 25°C (59°F to 77°F). Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
15 presentations of Ketorolac, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ketorolac 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Ketorolac 30 mg/1 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Ketorolac 15 mg/1 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Ketorolac 60 mg/2 mL injectionIntramuscularGeneric name | — | US FDA | Available on request |
| Ketorolac 5 mg/mL ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
| Ketorolac 5 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Ketorolac 60 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Ketorolac 30 mg/1 mL injectionIntramuscularGeneric name | — | US FDA | Available on request |
| Ketorolac 4 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Ketrolac Tromethamine 15 mg/1 mL injectionIntramuscular, intravenous | Anthea PharmaIndia | US FDA | Available on request |
| Sprix 15.75 mg nasal sprayNasal Cold chain | Zyla Life Sciences | US FDA | Available on request |
| Acular 5 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Acular LS 4 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Acuvail 4.5 mg/mL eye dropsOphthalmic | Allergan | US FDA | Available on request |
| Ketorolac 30 mg/mL injectionIntramuscularGeneric name | — | US FDA | Available on request |
5 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 November 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Ketorolac in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 15 presentations of Ketorolac and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Anthea Pharma.
The catalogue lists 5 brand names for Ketorolac, including Acular, Acular LS, Acuvail, Ketrolac Tromethamine, Sprix.
Yes. The US FDA first approved Ketorolac on 30 November 1989, according to Drugs@FDA.
At least one listed presentation of Ketorolac must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Ketorolac is classified under ATC code M01AB15 (Ketorolac).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.